Participants 96 159 7
elderly adults with newly diagnosed acute myelogenous leukemia.
Participants 204 273 4
elderly adults with newly diagnosed acute myelogenous leukemia (AML).
Participants 435 559 6
phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy.
